10 Dec 2018 17:59
CIRCASSIA PHARMACEUTICALS PLC
POSTING OF SHAREHOLDER CIRCULAR
Oxford, UK - 10 December 2018: Circassia Pharmaceuticals plc ("Circassia" or "the Company") (LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces that further to the announcement earlier today, a Circular has been published and will be posted to shareholders today in relation to the proposed cancellation of ordinary shares from the Official List and Admission to trading on AIM. The Circular contains the notice convening the General Meeting to be held at the offices of Circassia Pharmaceuticals plc, Northbrook House, Robert Robinson Avenue, The Oxford Science Park, Oxford, Oxfordshire, OX4 4GA, United Kingdom at 12 midday on 4 January 2019.
A copy of the Circular will shortly be available on the Company's website at www.circassia.com.
Enquiries
Circassia |
|
Steve Harris, Chief Executive Officer | Tel: +44 (0) 1865 405 560 |
Julien Cotta, Chief Financial Officer |
|
Rob Budge, Corporate Communications |
|
|
|
Peel Hunt |
|
James Steel / Dr. Christopher Golden | Tel: +44 (0) 20 7418 8900 |
|
|
Numis Securities |
|
James Black / Freddie Barnfield | Tel: +44 (0) 20 7260 1000 |
|
|
FTI Consulting |
|
Simon Conway / Mo Noonan | Tel: +44 (0) 20 3727 1000 |
About Circassia
Circassia is a world-class specialty pharmaceutical business focused on respiratory disease. Circassia sells its novel, market-leading NIOX® asthma management products directly to specialists in the United States, United Kingdom and Germany, and in a wide range of other countries through its network of partners. In 2017, the Company established a commercial collaboration with AstraZeneca in the United States in which it promotes the chronic obstructive pulmonary disease (COPD) treatment Tudorza® and has the commercial rights to NDA-stage COPD product Duaklir®. For more information please visit www.circassia.com.